Drug-facilitated weight loss benefits cardiometabolic status

Drug-facilitated weight loss benefits cardiometabolic status
Obese and overweight patients with dyslipidemia or hypertension treated with phentermine and topiramate extended-release (PHEN/TPM ER) for weight loss had significant improvements in cardiovascular disease risk factors, according to research published in the April 15 issue of The American Journal of Cardiology.

(HealthDay)—Obese and overweight patients with dyslipidemia or hypertension treated with phentermine and topiramate extended-release (PHEN/TPM ER) for weight loss had significant improvements in cardiovascular disease risk factors, according to research published in the April 15 issue of The American Journal of Cardiology.

Michael H. Davidson, M.D., of University of Chicago, and colleagues conducted a subgroup analysis of subjects with either hyperlipidemia or hypertension who participated in the CONQUER study, a randomized, double-blind, placebo-controlled, multi-center study, to determine changes in cardiometabolic risk factors in subjects treated with PHEN/TPM ER.

According to the researchers, in a subgroup of 647 patients with dyslipidemia or hypertension, treatment with either low or high dose of PHEN/TPM ER resulted in significantly greater percentage weight loss than patients treated with placebo. Independent of treatments, significantly greater reductions in triglycerides (-14.5 percent to -39.8 percent) and non-high-density lipoprotein cholesterol (-9.4 percent to -14.8 percent) were observed in patients with dyslipidemia who lost ≥ 5 percent of their weight than those who lost < 5 percent of their baseline weight. Patients with hypertension who lost ≥ 5 percent of their weight also had significantly greater reductions in systolic blood pressure (-7.5 to -11.8 mm Hg).

"The dose-related weight loss induced by PHEN/TPM ER, the associated beneficial effects on cardiometabolic risk factors, and the reductions in medication use indicate that PHEN/TPM ER treatment may be an important addition to the therapeutic armamentarium for obese and with comorbidities such as hypertension and dyslipidemia," the authors write.

The study was supported by VIVUS, Inc., Mountain View, California and several authors disclosed with pharmaceutical and biotechnology companies.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ECO: New weight loss drug effective in advanced obesity

date May 14, 2012

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related ...

Experimental drug helps diabetes patients lose weight

date Jun 25, 2012

An experimental drug helped significantly more overweight patients with diabetes shed pounds, compared with placebo, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting in Houston.

Experimental drug achieves unprecedented weight loss

date Apr 11, 2011

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers ...

Recommended for you

Catheterization increasing for seniors with STEMI

date 15 minutes ago

(HealthDay)—From 1999 to 2009 there was a decrease in the proportion of older adults with ST-segment elevation acute myocardial infarction (STEMI) who did not undergo cardiac catheterization, according ...

Race influences warfarin dose, study says

date 8 hours ago

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), propose ...

Even moderate BMI reduction could ease A-fib burden

date 11 hours ago

(HealthDay)—Incremental increases in body mass index (BMI) are associated with excess risk of incident, postoperative, and post-ablation atrial fibrillation (AF), according to a review published online ...

Personalized saline may provide solution to heart death

date 13 hours ago

Saline solution is a staple of every hospital. No matter the ailment, doctors have known for more than a century that saline is key to keeping patients hydrated and maintaining their blood pressure levels. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.